AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in early-stage stomach cancer met its main goal. When added to a ...

(RTTNews) - The Imfinzi-based regimen demonstrated a statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal ...

Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric and gastroesophageal junction cancers. Among patients with resectable ...

Imfinzi plus chemotherapy significantly improved event-free survival in resectable Stage II-IVA gastric and GEJ cancer patients. A strong trend in overall survival benefit was observed, with final ...

AstraZeneca (AZ) has shared positive results from a late-stage trial of its Imfinzi (durvalumab)-based perioperative regimen in gastric cancer. The phase 3 MATTERHORN study has been evaluating Imfinzi ...

The Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for adults with limited-stage small cell lung cancer (SCLC) whose disease did not progress after concurrent platinum-based ...

Recommendation based on AEGEAN Phase III trial results which showed Imfinzi reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca’s Imfinzi ...

Also Read: AstraZeneca’s Imfinzi Perioperative Regimen Shows Improved Survival Outcomes In Bladder Cancer Patients Patients were treated with neoadjuvant Imfinzi in combination with chemotherapy ...